Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
The return on assets (ROA) is N/A as of the fiscal period ended Tuesday, March 31, 2026.
Reported quarterly return on assets; no daily interpolation. Q4 FY2026 (2026-03-31): -1.72%.
RETURN ON ASSETS (ROA)
N/A
RETURN ON ASSETS (ROA) AVG TTM
7.00%
RETURN ON ASSETS (ROA) AVG 3Y
-3.42%
RETURN ON ASSETS (ROA) AVG 5Y
-4.05%
RETURN ON ASSETS (ROA) AVG 10Y
-5.66%
RETURN ON ASSETS (ROA) AVG 15Y
-3.70%
RETURN ON ASSETS (ROA) AVG 20Y
-4.23%
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Ridgetech, Inc.
Market Cap
$814420.00
Return on Assets (ROA)
N/A
TTM Avg
7.00%
3Y Avg
-3.42%
5Y Avg
-4.05%
Market Cap
$827771.00
Return on Assets (ROA)
-63.04%
TTM Avg
-106.06%
3Y Avg
-121.33%
5Y Avg
-96.21%
Market Cap
$835190.00
Return on Assets (ROA)
-160.53%
TTM Avg
-148.83%
3Y Avg
-175.96%
5Y Avg
-127.43%
Market Cap
$850879.00
Return on Assets (ROA)
-65.16%
TTM Avg
-80.06%
3Y Avg
-104.26%
5Y Avg
-73.53%
Market Cap
$879977.00
Return on Assets (ROA)
-17.34%
TTM Avg
-18.34%
3Y Avg
-35.92%
5Y Avg
-162.42%
Market Cap
$726206.00
Return on Assets (ROA)
N/A
TTM Avg
-16.55%
3Y Avg
-16.64%
5Y Avg
-15.27%
Market Cap
$894080.00
Return on Assets (ROA)
-1066.69%
TTM Avg
-314.14%
3Y Avg
-238.72%
5Y Avg
-174.21%
Market Cap
$695428.00
Return on Assets (ROA)
2.60%
TTM Avg
-212.84%
3Y Avg
-24543.27%
5Y Avg
-19977.79%
Market Cap
$1.02M
Return on Assets (ROA)
-81.60%
TTM Avg
-1375.39%
3Y Avg
-681.84%
5Y Avg
-547.21%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Ridgetech, Inc. (RDGT) | $814420.00 | N/A | 7.00% | -3.42% | -4.05% |
| Bluejay Diagnostics, Inc. (BJDX)vs › | $827771.00 | -63.04% | -106.06% | -121.33% | -96.21% |
| Decoy Therapeutics Inc. (DCOY)vs › | $835190.00 | -160.53% | -148.83% | -175.96% | -127.43% |
| Bone Biologics Corporation (BBLG)vs › | $850879.00 | -65.16% | -80.06% | -104.26% | -73.53% |
| Sunshine Biopharma, Inc. (SBFM)vs › | $879977.00 | -17.34% | -18.34% | -35.92% | -162.42% |
| China SXT Pharmaceuticals, Inc. (SXTC)vs › | $726206.00 | N/A | -16.55% | -16.64% | -15.27% |
| GlucoTrack, Inc. (GCTK)vs › | $894080.00 | -1066.69% | -314.14% | -238.72% | -174.21% |
| CDT Equity Inc. (CDT)vs › | $695428.00 | 2.60% | -212.84% | -24543.27% | -19977.79% |
| Aspire Biopharma Holdings, Inc. (ASBP)vs › | $1.02M | -81.60% | -1375.39% | -681.84% | -547.21% |
| HCW Biologics Inc. (HCWB)vs › | $566203.00 | -18.39% | -65.88% | -62.81% | -52.14% |
ROA
N/A
ROE
N/A
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2026-03-31 | -1.81% |
| 2025-03-31 | 15.81% |
| 2024-03-31 | -4.45% |
| 2023-03-31 | -23.24% |
| 2022-03-31 | -3.00% |
| 2021-03-31 | -7.64% |
| 2020-03-31 | -5.84% |
| 2019-03-31 | -1.27% |
| 2018-03-31 | -23.11% |
| 2017-03-31 | -8.40% |
| 2016-03-31 | 0.72% |
| 2015-03-31 | 1.44% |
| 2014-03-31 | -55.23% |
| 2013-03-31 | -21.13% |
| 2012-03-31 | 10.86% |
| 2011-03-31 | 15.63% |
| 2010-03-31 | 40.89% |
| 2008-07-31 | -1790.04% |
| 2007-07-31 | -12.31% |
